Search
forLearn
5 / 801 resultslearn Tripeptide-1
learn copper tripeptide-1
learn HT-B
learn ACETYL TETRAPEPTIDE-2
Research
5 / 264 results
research Skin Adipocyte Stem Cell Self-Renewal Is Regulated by a PDGFA/AKT-Signaling Axis
PDGFA/AKT signaling is important for the growth and maintenance of certain skin fat cells.
research Expression of AKT1 along with AKT2 in granulosa-lutein cells of hyperandrogenic PCOS patients
The study found that women with hyperandrogenic PCOS have higher levels of AKT1 and AKT2 proteins in their cells, which may lead to cell dysfunction.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Effect of Scenedesmus deserticola JD052 Extracts on Hair Inductivity by Regulating the AKT and GSK3β/β-Catenin Signaling Pathways in Human Dermal Papilla Cells
Scenedesmus deserticola JD052 extracts may help hair growth and could be a natural treatment for hair loss.
research Ginsenoside Rb1 promotes the growth of mink hair follicle via PI3K/AKT/GSK-3β signaling pathway
Ginsenoside Rb1 from Panax ginseng helps mink hair grow by activating certain cell signals.
Community Join
5 / 1000+ resultscommunity Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Kintor’s GT20029 Phase 1 success
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
community Kintors 1% Pyrilutamide comes in October/November
Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.